Immunoprecise Antibodies LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Ingalls & Snyder LLC has reported beneficial ownership of 5.8% of MindWalk Holdings Corp.'s common stock as of December 31, 2025.
Charmquark TWEE and Charmquark EEN jointly report beneficial ownership of 11.6% of ImmunoPrecise Antibodies Ltd.'s common shares as of December 31, 2024.